Monotherapy in advanced prostate cancer: An overview

Experimental Oncology

Volumn 26, Issue 3, 2004, Pages 185-191

  Baltogiannis, Dimitrios ^a   Giannakopoulos, Xenophon ^a   Charalabopoulos, Kostas ^a   Sofikitis, Nikolaos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Advanced prostate cancer; Antiandrogens; Monotherapy

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTRADIOL UNDECYLATE; ESTROGEN; ETHINYLESTRADIOL; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; MEDROXYPROGESTERONE ACETATE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANDROGEN; ESTROGEN DERIVATIVE; HYDROXYPROGESTERONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE; STEROID; TESTOSTERONE;

ADVANCED CANCER; ALCOHOL INTOLERANCE; ANEMIA; ANOREXIA; BREAST TENDERNESS; CANCER HORMONE THERAPY; CARDIOVASCULAR DISEASE; CASTRATION; DIARRHEA; FATIGUE; GYNECOMASTIA; HOT FLUSH; HUMAN; LIBIDO DISORDER; LIVER FAILURE; LIVER TOXICITY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE ATROPHY; NAUSEA; ORCHIECTOMY; OSTEOPOROSIS; PATIENT COMPLIANCE; PNEUMONIA; PRACTICE GUIDELINE; PROSTATE CANCER; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; THROMBOEMBOLISM; VERTIGO; VISUAL DISORDER; VOMITING; WEIGHT GAIN; ARTICLE; CANCER GROWTH; CANCER STAGING; DOSE RESPONSE; DRUG ACTIVITY; DRUG INHIBITION; DRUG STRUCTURE; GENE CONTROL; MEDICAL RESEARCH; MUSCLE MASS; POTENCY DISORDER; QUALITY OF LIFE; SURGICAL TECHNIQUE; TOXICITY;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; CYPROTERONE ACETATE; DIHYDROTESTOSTERONE; ESTROGENS; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMIDAZOLIDINES; MALE; ORCHIECTOMY; PALLIATIVE CARE; PROGESTERONE CONGENERS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TESTOSTERONE;

EID: 7044236928     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Schroder FH. In: Campbell's urology. Walsh, Retik, Stamen and Vaughan, eds. W.B. Saunders: Philadelphia-London-Toronto-Montreal-Sydney-Tokyo, 1997; 2627-43.
2. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994; 13: 996-04.
3. Newling DW. Anti-androgens in the treatment of prostate cancer. Br J Urol 1996; 77: 776-84.
4. Geller J, Albert JD. Comparison of various hormone therapies for prostate carcinoma. Seminars in Oncol 1983; 10: 34-42.
5. Jacobi GH, Altwein J, Kurth KH, Basting R, Hohenfellner R. Treatment of advanced prostatic cancer with parenteral cyproterone acetate. Brit J Urol 1980; 52: 208-9.
6. Schroder FH. Antiandrogenic substances in the management of prostatic cancer. Recent Results Cancer Res 1990; 118: 163-73.
7. De Voogt HJ. Cyproterone acetate as monotherapy in prospective randomized trials. Prog Clin Biol Res 1990; 359: 85-91.
8. De Voogt HJ. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer. Prostate Suppl 1992; 4: 91-5.
9. Goldenberg SL, Bruchovsky N. Use of cyproterone acetate in prostate cancer. Urol Clin North Am 1991; 18: 111-22.
10. Schroeder FH. Reported to the Committee on the management of newly diagnosed metastatic prostate cancer. In "First International Consultation on Prostate Cancer". Murphy GP, Denis LJ, Chatelain C, Griffiths K, Khoury S, Cockett ATK, eds. S.C.L: Paris, 1997; 284.
11. Kolvenbag GJ, Blackledge GR, Gotting-Smith K. Bicahitamide in the treatment of prostate cancer: history of clinical development. Prostate 1998; 34: 61-72.
12. Kaisary A, Klarskov P, McKillop D. Absence of hepatic enzyme induction in prostate cancer patients receiving bicalutamide. Anticancer Drugs 1996; 7: 54-9.
13. Kaisary AV. Antiandrogen monotherapy in the management of advanced prostate cancer. Eur Urol 1997; 31: 14-9.
14. Schroder FH. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma. Prog Clin Biol Res 1990; 359: 93-03.
15. Pescatore P, Hammel P, Durand F, Bertheau P, Bernuau J, Huc D, Gerbal JL, Degott C, Benhamou JP. Fatal fulminant hepatitis induced by nilutamide. Gastroenterol Clin Biol 1993; 17: 499-01.
16. Kolvenbag GJ, Blackledge GR. Worldwide activity and safety of bicalutamide: a summary review. Urology 1996; 47: 70-9.
17. Chodak GW. Bicalutamide-associated fulminant hepatic failure. Urology 1997; 50: 1027.
18. Dawson LA, Chow E, Morton G. Fulminant hepatic failure associated with bicalutamide. Urology 1997; 49: 283-4.
19. Schellhammer PF. Fulminant hepatic failure associated with bicalutamide. Urology 1997; 50: 827.
20. Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomized trial. Br J Urol 1980; 52: 208-15.
21. Pavone-Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986; 136: 624-31.
22. Moffat LE. Comparison of goserelin acetate, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990; 18: 26-7.
23. Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O'Boyle PJ. A prospective, randomized study to compare goserelin acetate versus cyproterone acetate versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29: 47-54.
24. Lund F, Rasmussen F. Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. Br J Urol 1988; 61: 140-2.
25. Delaere KP, Van Thillo EL. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 1991; 18: 13-8.
26. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-7.
27. Modena MG, Grimaldi T, Origliani G, Fantini G, Rossi R. Menopause and cardiovascular risk. Pathophysiol Haemost Thromb 2002; 32: 8.
28. Di Micco P, D'Uva M. To understand the two way clinical association between cancer and thrombophilia. Exp Oncol 2003; 25: 243-4.
29. Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, Witte R, Schinella R, Trump D. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14: 2250-7.
30. Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997; 32: 391-5.
31. Oosterlinck W, Casselman J, Mattelaer J, Van Velthoven R, Kurjatkin O, Schulman C. Tolerability and safety of flutamide in monotherapy, with orchidectomy or with LHRH-a in advanced prostate cancer patients. A Belgian multicenter study of 905 patients. Eur Urol 1996; 30: 458-63.
32. Schroder FH, et al. Antiadrogens as monotherapy for metastatic prostate cancer: a preliminary report on EORTC protocol 30892. 1-141-146. The Parthenon Publishing Group, Rotterdam, 1996.
33. Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MC, Costantini M, Martorana G, Giuliani L. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 1991; 146: 377-81.
34. Dole EJ, Holdsworth MT. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother 1997; 31: 65-75.
35. Blackledge GR. Clinical progress with a new antiandrogen, bicalutamide. Eur Urol 1996; 29: 96-104.
36. Kolvenbag GJ, Blackledge GR. Worldwide activity and safety of bicalutamide: a summary review. Urology 1996; 47: 70-9.
37. McLeod DG, Kolvenbag GJ. Defining the role of antiandrogens in the treatment of prostate cancer. Urology 1996; 47: 85-9.
38. Lunglmayr G. Efficacy and tolerability of bicalutamide in patients with advanced prostate cancer. International Casodex Study Group. Anticancer Drugs 1995; 6: 508-13.
39. Tyrrell CJ. Tolerability and quality of life aspects with the anti-androgen Bicalutamide (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators. Eur Urol 1994; 26: 15-9.
40. Chatelain C, Rousseau V, Cosaert J. French multicentre trial comparing Bicalutamide (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report. Eur Urol 1994; 26: 10-4.
41. Verhelst J, Denis L, Van Vliet P, Van Poppel H, Braeckman J, Van Cangh P, Mattelaer J, D'Hulster D, Mahler C. Endocrine profiles during administration of the new non-steroidal anti-androgen Bicalutamide in prostate cancer. Clin Endocrinol 1994; 41: 525-30.
42. Soloway MS, Schellhammer PF, Smith JA, Chodak GW, Vogelzang NJ, Kennealey GT. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. J Urol 1995; 154: 2110-4.
43. Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of bicalutamide vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Eur Urol 1996; 29: 105-9.
44. Soloway MS, Schellhammer PF, Smith JA, Chodak GW, Kennealey GT. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. Urology 1996; 47: 33-7.
45. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996; 47: 38-43.
46. Iversen P, Tveter K, Varenhorst E. Randomized study of Bicalutamide 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scand J Urol Nephrol 1996; 30: 93-8.
47. Iversen P. Update of monotherapy trials with the new antiandrogen, Bicalutamide (ICI 176,334). International Casodex Investigators. Eur Urol 1994; 26: 5-9.
48. Iversen P, Kaisary A, Tyrrell C, Anderson I, Baert L, Tammela T, Chamberlain M. A randomized comparison of bicalutamide 150 mg versus castration in the treatment of advanced prostate cancer. Eur Urol 1998; 33: 347.
49. Iversen J, Iversen P, Kaisary A, Tyrrell C, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G. Improvements in quality of live for patients treated with a nonsteroidal antiandrogens (bicalutamide) 150 mg as monotherapy compared to castration. Eur Urol 1998; 33: 348.
50. Huggins C, Stevens RE, Hodges CV. Studies on prostate cancer. Arch Surg 1941; 43: 209-23.
51. Huggins C, Hodges CV. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum posphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
52. Huggins C, Clark PJ. Quantitative studies of prostate secretion. II. The effects of castration and of estrogen injection on the normal and on the hyperplastic prostate glands of dogs. J Exp Med 1940; 72: 747-53.
53. Moore RA. Benign hypertrophy and carcinoma of the prostate: occurrence and experimental production in animals. Surgery 1944; 16: 152-67.
54. White JW. The results of double castration in hypertrophy of the prostate. Ann Surg 1895; 22: 1-80.
55. Cabot AT. The question of castration for enlarged prostate. Ann Surg 1896; 24: 265-309.
56. Burge PD, Harper ME, Hartog M, Gingell JC. Subcapsular orchidectomy: an effective operation? Proc Royal Soc Med 1976; 69: 663-4.
57. Dodds EC, Goldberg L, Lawson W, Robinson R. Oestrogenic activity of certain oestrogenic compounds. Nature 1938; 141: 241-8.
58. Resnick MI, Grayhack JT. Treatment of stage IV carcinoma of the prostate. Urol Clin North Am 1975; 2: 141-61.
59. Jordan WB, Blackard CE, Byar DP. Reconsideration of orchidectomy in the treatment of advanced prostatic carcinoma. Southern Med J 1977; 70: 1411-3.
60. Mellinger GT. Veterans Admin Coop Urological Res Group. Carcinoma of the prostate: a continuing cooperative study. J Urol 1964; 91: 590-4.
61. Arduino LJ. Veterans Admin Coop Urological Res Group. Carcinoma of the prostate: treatment and comparison. J Urol 1967; 98: 516-22.
62. Smith PH. Hormone therapy: an overview. In: Preventing prostate cancer: screening versus chemo-prevention. ICRF 0-87969-466-1/95. Cancer Surveys; 1995; 23: 171-81.
63. Huggins C. Endocrine-induced regression of cancers. In "Les Prix Nobel en 1966". Stockholm, Imprimerie Royale: P.a. Norstedt & Soner, 1967; 172-82.
64. Griffiths K, Denis LJ, Turkes A, Morton MS. Possible relationship between dietary factors and pathogenesis of prostate cancer. Int J Urol 1998; 5: 195-13.
65. Denis LJ. Staging and prognosis of prostate cancer. Eur Urol 1993; 24: 13-9.
66. rd International Consultation on BPH. Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis LJ, Griffiths K, Murphy G, eds. S.C.L. Paris: 1996; 73-115.
67. th International Consultation on BPH. Denis LJ, Cockett ATK, Chatelain C, Griffiths K, Khoury S, Murphy G, eds. S.C.L. Paris: 1998; 85-128.
68. Isaacs JT, Cussenot O, Jankevicius F, Klocker H, Kubota Y, Morgia G, Rennie P, Schmitz-Drager BJ. Growth regulation of normal and malignant prostatic cells. In: First International Consultation on Prostate Cancer. Murphy G, Denis LJ, Chatelain C, Griffiths K, Khoury S, Cockett ATK, eds. S.C.L. Paris: 1997; 31-81.
69. Truss M, Beato M. Steroid hormone receptors: Interaction with deoxyribonucleic acid and transcription factors. Endocr Revs 1993; 14: 459-79.
70. Griffiths K, Eaton CL, Harper ME, Weir AMK, Evans BAJ. Some aspects of the molecular endocrinology of prostatic cancer. In: Antiandrogens in prostate cancer. Denis LJ, ed. ESO Monographs: Springer, 1996; 3-29.
71. Denis LJ. Controversies in the management of localized and metastatic prostate cancer. Eur J Cancer 1991; 27: 333-41.
72. Kaisary AV. Compliance with hormonal treatment for prostate cancer. Br J Hosp Med 1996; 55: 359-66.
73. Second international consultation on prostate cancer. Murphy G, Khoury S, Partin A, Denis LJ, eds. S.C.L.: Paris, 1999.
74. Prostate cancer trialists' collaborative group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-8.
75. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, Conti G, Cruciani G, Dammino S, Delliponti U, Ditonno P, Ferraris V, Lilliu S, Montefiore F, Portoghese F, Spano G. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian prostate cancer project study. J Clin Oncol 1999; 17: 2027-38.
76. Iversen P. Antiandrogen monotherapy. In: Progress and controversies in urological oncology. Schroeder FH, ed. Parthenon, 1999.
77. Iverson P, Tyrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Carroll K, Gotting-Smith K, Blackledge GR. Bicalutamide 150 mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer results from two multicentre randomized trials at a median follow-up of 4 years. Urology 1998; 51: 389-96.
78. Iversen P, Tyrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinck I. Bicalutamide 150 mg monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years follow-up. J Urol 2000; 164: 1579-82.